Milestone Pharmaceuticals (MIST) EBIT Margin (2021 - 2022)
Milestone Pharmaceuticals' (MIST) quarterly EBIT Margin came in at 1002.0% in Q3 2022, down 21209.55% on a QoQ basis from 4.75% in Q2 2021.
Milestone Pharmaceuticals (MIST) EBIT Margin (2021 - 2022) Analysis & Trends
Milestone Pharmaceuticals (MIST) has 2 years of EBIT Margin data on file, last reported at 1002.0% in Q3 2022.
- Quarterly EBIT Margin changed N/A year-over-year to 1002.0% in Q3 2022, while the trailing twelve-month figure through Sep 2022 was 381.98% (changed N/A YoY) and the FY2021 annual result came in at 287.15%, changed N/A from the prior year.
- EBIT Margin slipped to 1002.0% in Q3 2022, from 4.75% in the prior quarter.
- In the past five years, EBIT Margin ranged from a high of 4.75% in Q2 2021 to a low of 1002.0% in Q3 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 37.40% |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 30.15% |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 32.54% |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -562.07% |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 19.06% |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 17.93% |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -0.36% |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 19.75% |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -35.57% |
| 10 | Milestone Pharmaceuticals | 42.70 Mn | -128.80 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2022 | -1,002.00% |
| Jun 30, 2021 | 4.75% |